乌药通过调控p38MAPK/ERK通路对脂多糖诱导小鼠急性呼吸窘迫综合征的保护作用
研究将40只C57BL/6小鼠随机分为假手术组、ARDS模型组、低剂量乌药(L-LA)组和高剂量乌药(H-LA)组,每组10只。ARDS模型经气管注射5 mg/kg脂多糖建立;L-LA组和H-LA组分别每日一次灌胃1 g/kg和5 g/kg乌药提取物,造模前预给药3天、造模后继续给药2天。结果显示,H-LA组肺湿/干重比、血清和BALF中TNF-α与IL-6、BALF巨噬细胞CD40表达率及肺组织p38、ERK1/2磷酸化水平均显著低于ARDS模型组和L-LA组(均P<0.01),肺组织病理损伤也较轻;L-LA组上述指标与ARDS模型组无显著差异。作者认为乌药可抑制LPS诱导的肺部炎症、减轻ARDS小鼠肺损伤,机制可能与抑制p38MAPK/ERK信号通路激活有关。
要点
- 高剂量乌药(5 g/kg灌胃,每日一次,造模前3天预给药并持续至造模后2天)可降低ARDS小鼠肺湿/干重比(5.70±0.19 vs 模型组6.20±0.31,P<0.01)。
- 高剂量乌药组血清TNF-α(83.63±15.04 ng/L vs 模型组111.75±18.45 ng/L)和IL-6(111.38±8.75 ng/L vs 244.13±26.85 ng/L)均显著低于模型组(均P<0.01)。
- 高剂量乌药组BALF中TNF-α(36.25±2.82 ng/L vs 51.13±5.44 ng/L)和IL-6(35.63±2.20 ng/L vs 49.63±4.90 ng/L)显著低于模型组(均P<0.01)。
- 高剂量乌药组BALF巨噬细胞CD40表达率(23.28±2.45% vs 30.32±2.40%)及肺组织p-p38/p38(0.50±0.04 vs 0.74±0.07)、p-ERK1/2/ERK1/2(0.47±0.07 vs 0.72±0.07)均显著低于模型组(均P<0.01)。
- 低剂量乌药(1 g/kg)组上述指标与ARDS模型组无显著差异,光镜下肺组织病理特征也与模型组无显著差异。
适用人群与场景
- C57BL/6小鼠,共40只,随机分为假手术组、ARDS模型组、低剂量乌药组和高剂量乌药组,每组10只;经气管注射5 mg/kg脂多糖建立ARDS模型。
处置流程与药物剂量
- 低剂量乌药组:乌药提取物1 g/kg灌胃,每日一次,造模前预给药3天,造模后继续给药2天。
- 高剂量乌药组:乌药提取物5 g/kg灌胃,每日一次,造模前预给药3天,造模后继续给药2天。
- ARDS模型组:给予同体积生理盐水;假手术组不接受治疗。
研究设计与关键结果
- 研究类型为小鼠实验;40只C57BL/6小鼠随机分为假手术组、ARDS模型组、低剂量乌药(L-LA)组和高剂量乌药(H-LA)组,每组10只;ARDS模型经气管注射5 mg/kg脂多糖建立。
- 光镜下H-LA组肺泡结构破坏、肺泡间隔增厚和炎症细胞浸润较ARDS模型组轻,而L-LA组ARDS病理特征与模型组无显著差异。
- 与假手术组比较,ARDS模型组肺湿/干重比、血清和BALF中TNF-α与IL-6蛋白含量、BALF巨噬细胞CD40表达率及肺组织p38、ERK1/2蛋白磷酸化水平均显著升高。
- L-LA组肺湿/干重比、血清和BALF中TNF-α与IL-6浓度、BALF巨噬细胞CD40表达率及肺组织p38、ERK1/2蛋白磷酸化水平与ARDS模型组无显著差异。
- H-LA组上述指标均显著低于ARDS模型组和L-LA组:肺湿/干重比5.70±0.19 vs 6.20±0.31、6.01±0.17;血清TNF-α(ng/L)83.63±15.04 vs 111.75±18.45、108.12±13.98;血清IL-6(ng/L)111.38±8.75 vs 244.13±26.85、227.50±9.37;BALF TNF-α(ng/L)36.25±2.82 vs 51.13±5.44、47.50±5.78;BALF IL-6(ng/L)35.63±2.20 vs 49.63±4.90、46.38±3.50;CD40表达率(%)23.28±2.45 vs 30.32±2.40、28.17±1.98;p-p38/p38 0.50±0.04 vs 0.74±0.07、0.69±0.04;
证据类型、等级与局限
- 证据类型:小鼠实验(动物实验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为乌药可抑制脂多糖诱导的ARDS小鼠肺部炎症并减轻肺损伤,机制可能与抑制p38MAPK/ERK信号通路激活有关;该结论来自小鼠实验,原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the protective effect of Lindera aggregata on acute respiratory distress syndrome (ARDS) induced by lipopolysaccharide (LPS) in mice and its possible mechanism.
METHODS: Forty C57BL/6 mice were randomly divided into sham operation group, ARDS model group, low-dose Lindera aggregata (L-LA) group and high-dose Lindera aggregata (H-LA) group, with 10 mice in each group. ARDS model was established by injecting 5 mg/kg LPS through the trachea. The L-LA group and H-LA group were orally administrated 1 g/kg and 5 g/kg of the Lindera aggregate extract once a day, respectively, while the ARDS model group was given the same volume of normal saline, the sham group received no treatment. The Lindera aggregata was preadministered for 3 days before modeling, and continued for 2 days after modeling, then the animals were sacrificed, and bronchoalveolar lavage fluid (BALF) and lung tissue were collected. The pathological changes of lung tissue in each group of mice were observed under the microscope and the wet/dry weight ratio (W/D) of the lung were measured. Enzyme linked immunosorbent assay (ELISA) was used to examine the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in mice serum and BALF, and flow cytometry was used to detect the expression rate of CD40 on the surface of BALF macrophages. The phosphorylation levels of p38 and extracellular signal-regulated protein kinase 1/2 (ERK1/2) proteins in lung tissue were measured by Western blotting.
RESULTS: Lung histopathology under light microscope showed that the damage of alveolar structure, thickening of alveolar septum and infiltration of inflammatory cells in the H-LA group were less severe than those in the ARDS model group, while the pathological characteristics of ARDS in the L-LA group were not significantly different from those in the ARDS model group. Compared with the sham operation group, the lung W/D ratio, TNF-α and IL-6 protein contents in serum and BALF, BALF macrophage CD40 expression rate and lung tissue p38 and ERK1/2 protein phosphorylation levels were significantly increased in ARDS model group. The W/D ratio, the concentrations of TNF-α and IL-6 in serum and BALF, the expression rate of CD40 in BALF macrophages, and the phosphorylation levels of p38 and ERK1/2 protein in lung tissue in the L-LA group were not significantly different from those in the ARDS model group. The above indexes in the H-LA group were significantly lower than those in the ARDS model group and the L-LA group [W/D ratio: 5.70±0.19 vs. 6.20±0.31, 6.01±0.17; serum TNF-α (ng/L): 83.63±15.04 vs. 111.75±18.45, 108.12±13.98; serum IL-6 (ng/L): 111.38±8.75 vs. 244.13±26.85, 227.50±9.37; BALF TNF-α (ng/L): 36.25±2.82 vs. 51.13±5.44, 47.50±5.78; BALF IL-6 (ng/L): 35.63±2.20 vs. 49.63±4.90, 46.38±3.50; CD40 expression rate (%): 23.28±2.45 vs. 30.32±2.40, 28.17±1.98; p-p38/p38: 0.50±0.04 vs. 0.74±0.07, 0.69±0.04; p-ERK1/2/ERK1/2: 0.47±0.07 vs. 0.72±0.07, 0.68±0.05; all P < 0.01].
CONCLUSIONS: Lindera aggregata can inhibit LPS-induced lung inflammation and alleviate lung injury in ARDS mice. The mechanism may be related to the inhibition of the activation of p38 mitogen activated protein kinase/ERK (p38MAPK/ERK) signaling pathway.
参考来源
- Lu M, Fan L, Xu M, et al. [Protective effect of Lindera aggregata on lipopolysaccharide-induced mice acute respiratory distress syndrome by regulating p38MAPK/ERK pathway]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36377449. doi:10.3760/cma.j.cn121430-20210317-00389
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。